Graziano Lolli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6480406/publications.pdf

Version: 2024-02-01

37	1,622	331670 21	345221 36
papers	citations	h-index	g-index

39	39	39	2383
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pharmacological inactivation of the prion protein by targeting a folding intermediate. Communications Biology, 2021, 4, 62.	4.4	30
2	Identification of a BAZ2A Bromodomain Hit Compound by Fragment Joining. ACS Bio & Med Chem Au, 2021, 1, 5-10.	3.7	3
3	Identification of compounds inhibiting prion replication and toxicity by removing PrP^C from the cell surface. Journal of Neurochemistry, 2020, 152, 136-150.	3.9	11
4	Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin. FEBS Journal, 2020, 287, 1850-1864.	4.7	9
5	A novel class of selective CK2 inhibitors targeting its open hinge conformation. European Journal of Medicinal Chemistry, 2020, 195, 112267.	5.5	15
6	Inhibitory Properties of ATP-Competitive Coumestrol and Boldine Are Correlated to Different Modulations of CK2 Flexibility. Journal of Natural Products, 2019, 82, 1014-1018.	3.0	4
7	Screening Approaches for Targeting Ribonucleoprotein Complexes: A New Dimension for Drug Discovery. SLAS Discovery, 2019, 24, 314-331.	2.7	29
8	Insight into GFPmut2 pH Dependence by Single Crystal Microspectrophotometry and X-ray Crystallography. Journal of Physical Chemistry B, 2018, 122, 11326-11337.	2.6	3
9	Structural Analysis of Smallâ€Molecule Binding to the BAZ2A and BAZ2B Bromodomains. ChemMedChem, 2018, 13, 1479-1487.	3.2	11
10	Characterization of the oligomeric states of the CK2 Î±2Î²2 holoenzyme in solution. Biochemical Journal, 2017, 474, 2405-2416.	3.7	17
11	Discovery of BAZ2A bromodomain ligands. European Journal of Medicinal Chemistry, 2017, 139, 564-572.	5.5	21
12	Discovery of Inhibitors of Four Bromodomains by Fragment-Anchored Ligand Docking. Journal of Chemical Information and Modeling, 2017, 57, 2584-2597.	5.4	21
13	Derivatives of 3-Amino-2-methylpyridine as BAZ2B Bromodomain Ligands: In Silico Discovery and in Crystallo Validation. Journal of Medicinal Chemistry, 2016, 59, 9919-9927.	6.4	23
14	The â€œGatekeeperâ€•Residue Influences the Mode of Binding of Acetyl Indoles to Bromodomains. Journal of Medicinal Chemistry, 2016, 59, 3087-3097.	6.4	36
15	The STAS domain of mammalian SLC26A5 prestin harbours an anion-binding site. Biochemical Journal, 2016, 473, 365-370.	3.7	24
16	High-Throughput Fragment Docking into the BAZ2B Bromodomain: Efficient in Silico Screening for X-Ray Crystallography. ACS Chemical Biology, 2016, 11, 800-807.	3.4	32
17	Structural Basis of CK2 Regulation by Autoinhibitory Oligomerization. , 2015, , 35-47.		2
18	Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential. Cellular and Molecular Life Sciences, 2014, 71, 3173-3185.	5.4	45

#	Article	IF	Citations
19	The lysine-specific demethylase 1 is a novel substrate of protein kinase CK2. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 722-729.	2.3	9
20	Active Form of the Protein Kinase CK2 Î±₂Î²₂ Holoenzyme Is a Strong Complex with Symmetric Architecture. ACS Chemical Biology, 2014, 9, 366-371.	3.4	29
21	An Inhibitorâ€™s-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States. ACS Chemical Biology, 2014, 9, 1251-1256.	3.4	27
22	Different orientations of low-molecular-weight fragments in the binding pocket of a BRD4 bromodomain. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 2161-2164.	2.5	23
23	Inhibition of Protein Kinase CK2 by Flavonoids and Tyrphostins. A Structural Insight. Biochemistry, 2012, 51, 6097-6107.	2.5	127
24	Structural and functional analysis of the flexible regions of the catalytic Î±-subunit of protein kinase CK2. Journal of Structural Biology, 2012, 177, 382-391.	2.8	32
25	Structural Determinants of Protein Kinase CK2 Regulation by Autoinhibitory Polymerization. ACS Chemical Biology, 2012, 7, 1158-1163.	3.4	58
26	Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer. Biochemistry, 2011, 50, 8478-8488.	2.5	154
27	Structural and functional determinants of protein kinase CK2Î±: facts and open questions. Molecular and Cellular Biochemistry, 2011, 356, 67-73.	3.1	28
28	Structure and single crystal spectroscopy of Green Fluorescent Proteins. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 824-833.	2.3	12
29	Structural dissection of cyclin dependent kinases regulation and protein recognition properties. Cell Cycle, 2010, 9, 1551-1561.	2.6	41
30	The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO Journal, 2008, 27, 1907-1918.	7.8	295
31	Binding to DNA of the RNA-polymerase II C-terminal domain allows discrimination between Cdk7 and Cdk9 phosphorylation. Nucleic Acids Research, 2008, 37, 1260-1268.	14.5	18
32	Recognition of Cdk2 by Cdk7. Proteins: Structure, Function and Bioinformatics, 2007, 67, 1048-1059.	2.6	21
33	CAKâ€”Cyclin-Dependent Activating Kinase: A Key Kinase in Cell Cycle Control and a Target for Drugs?. Cell Cycle, 2005, 4, 565-570.	2.6	151
34	CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?. Cell Cycle, 2005, 4, 572-7.	2.6	67
35	The Crystal Structure of Human CDK7 and Its Protein Recognition Properties. Structure, 2004, 12, 2067-2079.	3.3	124
36	GroEL from the psychrophilic bacterium Pseudoalteromonas haloplanktis TAC 125: molecular characterization and gene cloning. Extremophiles, 2003, 7, 17-28.	2.3	33

#	Article	IF	Citations
37	Inhibitor affinity chromatography: Profiling the specific reactivity of the proteome with immobilized molecules. Proteomics, 2003, 3, 1287-1298.	2.2	33